Synthesize Bio, a Seattle-based startup founded by leaders from Fred Hutchinson Cancer Center, announced $10 million in funding from Madrona Venture Group to develop an AI platform that predicts gene expression.
The company’s GEM 1 model was trained on public RNA sequencing data and aims to accelerate experiments by simulating results from hypothetical lab tests. “Our vision is that somebody will start using our AI model and be able to do 10 times the science and make 10 times the discoveries that they are right now,” said co-founder Robert Bradley.
This funding further reflects Seattle’s leading position in generative genomics and AI-driven biomedical innovation.